---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-008293"
form_type: "8-K"
ticker: "ITRMF"
cik: "0001659323"
company_name: "Iterum Therapeutics plc"
filed_at: "2023-03-16T23:59:59+00:00"
generated_at: "2026-06-18T00:35:37.040638+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Iterum Therapeutics reports 2022 net loss $44.4M; cash $60.8M funds to mid-2024

## Summary
- Cash, cash equivalents and short-term investments $60.8M; expected to fund operations until mid-2024.
- Net loss Q4 2022 $5.1M, full year $44.4M; non-GAAP net loss $6.4M and $22.9M respectively.
- REASSURE trial enrollment ongoing, expected completion H1 2024; interim analysis at 50% enrollment H2 2023.
- Two new US patents issued for oral sulopenem (composition and method of use), expiring no earlier than 2039.
- Shareholder class action lawsuit dismissed with prejudice on January 25, 2023.

## SEC filing metadata
- accession: 0000950170-23-008293
- form_type: 8-K
- ticker: ITRMF
- cik: 0001659323
- company_name: Iterum Therapeutics plc
- filed_at: 2023-03-16T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1659323/000095017023008293/0000950170-23-008293-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1659323/000095017023008293/itrm-20230316.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-008293
- JSON: https://secwatch.observer/filing/0000950170-23-008293.json
- Plain text: https://secwatch.observer/filing/0000950170-23-008293.txt

## Key facts
- Earnings Releases
  Iterum Therapeutics plc reported fourth quarter and year ended December 31, 2022 results: net income Net loss for the fourth quarter and full year 2022 was $5.1 million and $44.4 million, respectively, compared to a net l.
  - Period: fourth quarter and year ended December 31, 2022
  - Net income: Net loss for the fourth quarter and full year 2022 was $5.1 million and $44.4 million, respectively, compared to a net l
  - Result: reported results
  source text: Iterum Therapeutics plc issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1659323/000095017023008293/0000950170-23-008293-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.